文献
J-GLOBAL ID:202202289569050258
整理番号:22A1025699
症例報告: 新規LDLR-ROS1融合を伴う切除可能ステージIIIA NSCLC患者における良好な生存利益を及ぼすアジュバントクリゾチニブ療法【JST・京大機械翻訳】
Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR-ROS1 Fusion
著者 (13件):
Chen An-guo
(Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China)
,
Chen Dong-sheng
(The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China)
,
Chen Dong-sheng
(Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, China)
,
Chen Dong-sheng
(The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China)
,
Li Si
(The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China)
,
Li Si
(Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, China)
,
Li Si
(The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China)
,
Zhao Le-le
(The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China)
,
Zhao Le-le
(Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, China)
,
Zhao Le-le
(The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China)
,
Xiao Ming-zhe
(The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China)
,
Xiao Ming-zhe
(Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, China)
,
Xiao Ming-zhe
(The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China)
資料名:
Frontiers in Oncology (Web)
(Frontiers in Oncology (Web))
巻:
12
ページ:
837219
発行年:
2022年
JST資料番号:
U7089A
ISSN:
2234-943X
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
スイス (CHE)
言語:
英語 (EN)